PDS BIOTECHNOLOGY CORP (PDSB)

Thursday's session: gap up and gap down stocks

Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

Conference call and webcast today at 8:30 a.m. Eastern Time...

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute at Cytokines 2024...

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation...

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Presentation of data will take place on Saturday, September 14, 2024...

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips PDS Biotechnology (NASDAQ:PDSB) just reported results for the second quarter of...

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q2 2024

PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the second quarter of 2024.

PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE...

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...

PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months...

Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

/CNW/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...

Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

/PRNewswire/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at...

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024

PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head...

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to...

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...

PDS Biotechnology Announces Details of Virtual KOL Event

Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to...

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck...

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023

PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023.

PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips PDS Biotechnology (NASDAQ:PDSB) just reported results for the fourth quarter of...

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head...

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage...

The 3 Most Undervalued Biotech Stocks to Buy in March 2024

 These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March. 

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells...

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the...

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage...

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage...

Tuesday Sector Laggards: Waste Management, Drugs

PDS Biotech appoints Lars Boesgaard as chief financial officer (NASDAQ:PDSB)

PDS Biotechnology appoints Lars Boesgaard as CFO, succeeding Matthew Hill, to strengthen financial management and drive clinical-stage immunotherapy firm's...

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage...